Ariëns LFM, van der Schaft J, Bakker DS, et al. - Researchers utilized data from a prospective multicenter registry named the BioDay registry, to determine if and how clinical response and serum biomarkers could be altered by 16 weeks of treatment with dupilumab in adult patients (n = 138) with moderate-severe atopic dermatitis (AD) in daily practice. To determine the 16-week clinical efficacy of dupilumab, they assessed the number of patients achieving EASI-50 (Eczema Area and Severity Index) or EASI-75, as well as patient-reported outcomes measures. Of the overall study sample, 84 (61%) patients had failed treatment on ≥ 2 immunosuppressive drugs. The mean percent change in EASI score at week 16 was estimated to be 73%. Following 16 weeks of therapy, 114 (86%) patients achieved the EASI-50 and 82 (62%) achieved EASI-75. Among patients with very difficult-to-treat AD who were seen in a daily practice setting, a significant improvement in disease severity and reduction in severity related serum biomarkers were reported as the consequences of treatment with dupilumab.